Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hyperalgesia | 22 | 2020 | 527 | 3.150 |
Why?
|
Receptors, sigma | 13 | 2019 | 46 | 2.510 |
Why?
|
Bee Venoms | 9 | 2018 | 23 | 1.500 |
Why?
|
Obsessive-Compulsive Disorder | 10 | 2018 | 1508 | 1.480 |
Why?
|
Clonidine | 6 | 2020 | 170 | 1.400 |
Why?
|
Spinal Cord | 27 | 2023 | 1813 | 1.370 |
Why?
|
Analgesics | 12 | 2023 | 1071 | 1.210 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 8 | 2019 | 903 | 1.110 |
Why?
|
Adrenergic alpha-2 Receptor Agonists | 3 | 2020 | 92 | 1.100 |
Why?
|
Panic Disorder | 2 | 2023 | 613 | 1.100 |
Why?
|
Ethylenediamines | 10 | 2016 | 57 | 1.070 |
Why?
|
Executive Function | 4 | 2019 | 1405 | 1.030 |
Why?
|
Neuralgia | 8 | 2020 | 622 | 0.930 |
Why?
|
Obsessive Behavior | 3 | 2013 | 51 | 0.890 |
Why?
|
Acupuncture Points | 7 | 2018 | 111 | 0.780 |
Why?
|
Peripheral Nervous System Diseases | 3 | 2019 | 716 | 0.740 |
Why?
|
Exercise Therapy | 2 | 2019 | 939 | 0.730 |
Why?
|
Neurons, Afferent | 2 | 2017 | 498 | 0.710 |
Why?
|
Evoked Potentials | 2 | 2017 | 1058 | 0.700 |
Why?
|
Receptors, Adrenergic, alpha-2 | 5 | 2020 | 69 | 0.700 |
Why?
|
TRPV Cation Channels | 4 | 2017 | 244 | 0.700 |
Why?
|
Posterior Horn Cells | 5 | 2008 | 87 | 0.690 |
Why?
|
Psychomotor Performance | 3 | 2017 | 1894 | 0.660 |
Why?
|
Valerian | 1 | 2019 | 4 | 0.650 |
Why?
|
Schizophrenia | 4 | 2019 | 6987 | 0.610 |
Why?
|
Olfaction Disorders | 1 | 2021 | 225 | 0.600 |
Why?
|
Bicycling | 1 | 2019 | 177 | 0.600 |
Why?
|
Pain | 15 | 2018 | 5100 | 0.600 |
Why?
|
Protein Kinase C | 3 | 2016 | 1207 | 0.590 |
Why?
|
Facial Nerve Diseases | 1 | 2017 | 49 | 0.580 |
Why?
|
Exercise | 3 | 2019 | 5954 | 0.570 |
Why?
|
Mice, Inbred ICR | 19 | 2019 | 363 | 0.570 |
Why?
|
Organoplatinum Compounds | 2 | 2016 | 408 | 0.570 |
Why?
|
Capsaicin | 4 | 2017 | 235 | 0.560 |
Why?
|
Hearing Loss, Sudden | 1 | 2017 | 45 | 0.560 |
Why?
|
Internal Capsule | 3 | 2018 | 138 | 0.540 |
Why?
|
Sinusitis | 2 | 2023 | 998 | 0.540 |
Why?
|
Anti-Anxiety Agents | 1 | 2019 | 405 | 0.520 |
Why?
|
Nitric Oxide Synthase Type I | 2 | 2019 | 175 | 0.520 |
Why?
|
Attention | 2 | 2017 | 2423 | 0.510 |
Why?
|
Rhinitis | 1 | 2023 | 754 | 0.510 |
Why?
|
Plant Extracts | 3 | 2019 | 499 | 0.510 |
Why?
|
Afferent Pathways | 2 | 2007 | 304 | 0.510 |
Why?
|
Electric Stimulation Therapy | 1 | 2021 | 637 | 0.490 |
Why?
|
Diterpenes | 3 | 2017 | 170 | 0.470 |
Why?
|
Formaldehyde | 6 | 2023 | 361 | 0.450 |
Why?
|
Facial Pain | 1 | 2015 | 122 | 0.440 |
Why?
|
Nociceptors | 2 | 2008 | 460 | 0.440 |
Why?
|
Immunoglobulin E | 1 | 2019 | 1506 | 0.420 |
Why?
|
Astrocytes | 7 | 2019 | 1349 | 0.410 |
Why?
|
Behavior, Addictive | 1 | 2018 | 428 | 0.410 |
Why?
|
Basal Ganglia | 2 | 2013 | 555 | 0.410 |
Why?
|
Compulsive Behavior | 1 | 2013 | 117 | 0.400 |
Why?
|
Gyrus Cinguli | 2 | 2016 | 1135 | 0.400 |
Why?
|
Alcoholism | 1 | 2023 | 1981 | 0.400 |
Why?
|
Nerve Tissue Proteins | 5 | 2017 | 4413 | 0.400 |
Why?
|
Injections, Spinal | 10 | 2018 | 318 | 0.400 |
Why?
|
Morpholines | 5 | 2016 | 584 | 0.390 |
Why?
|
Psychiatric Status Rating Scales | 7 | 2019 | 6030 | 0.390 |
Why?
|
Nerve Fibers | 1 | 2015 | 709 | 0.390 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2017 | 783 | 0.370 |
Why?
|
Acupuncture Therapy | 1 | 2015 | 486 | 0.370 |
Why?
|
Pain Measurement | 15 | 2018 | 3586 | 0.360 |
Why?
|
Alcohol Drinking | 2 | 2023 | 4045 | 0.350 |
Why?
|
Polypharmacy | 1 | 2013 | 307 | 0.350 |
Why?
|
Sex Characteristics | 1 | 2021 | 2649 | 0.350 |
Why?
|
Hypersensitivity | 1 | 2019 | 1173 | 0.340 |
Why?
|
Serine | 3 | 2019 | 831 | 0.340 |
Why?
|
Republic of Korea | 6 | 2020 | 592 | 0.330 |
Why?
|
Adrenergic alpha-Agonists | 2 | 2020 | 177 | 0.330 |
Why?
|
Rats, Sprague-Dawley | 19 | 2018 | 8144 | 0.310 |
Why?
|
Male | 67 | 2024 | 365203 | 0.310 |
Why?
|
Affective Symptoms | 1 | 2011 | 418 | 0.310 |
Why?
|
Electroencephalography | 5 | 2024 | 6317 | 0.290 |
Why?
|
Sciatic Neuropathy | 1 | 2007 | 76 | 0.280 |
Why?
|
Deep Brain Stimulation | 2 | 2013 | 851 | 0.280 |
Why?
|
Suicide, Attempted | 1 | 2016 | 1409 | 0.280 |
Why?
|
Disease Models, Animal | 23 | 2019 | 18354 | 0.280 |
Why?
|
Biological Dressings | 1 | 2006 | 30 | 0.270 |
Why?
|
Carrageenan | 5 | 2018 | 71 | 0.270 |
Why?
|
Acupuncture Analgesia | 1 | 2006 | 63 | 0.270 |
Why?
|
Pain Threshold | 6 | 2015 | 606 | 0.260 |
Why?
|
Fibroins | 1 | 2006 | 59 | 0.260 |
Why?
|
Internet | 1 | 2018 | 3112 | 0.250 |
Why?
|
Cognition Disorders | 1 | 2019 | 3985 | 0.240 |
Why?
|
Stress, Psychological | 2 | 2018 | 4530 | 0.240 |
Why?
|
Migraine Disorders | 1 | 2017 | 1713 | 0.240 |
Why?
|
Depressive Disorder, Major | 4 | 2020 | 4818 | 0.240 |
Why?
|
Adrenergic alpha-2 Receptor Antagonists | 4 | 2015 | 18 | 0.240 |
Why?
|
Alginates | 1 | 2006 | 250 | 0.240 |
Why?
|
Phosphorylation | 9 | 2019 | 8317 | 0.240 |
Why?
|
Emotions | 1 | 2016 | 2768 | 0.220 |
Why?
|
Rats | 19 | 2018 | 23786 | 0.220 |
Why?
|
Antipsychotic Agents | 2 | 2016 | 3081 | 0.220 |
Why?
|
Agoraphobia | 1 | 2023 | 177 | 0.220 |
Why?
|
Hot Temperature | 7 | 2017 | 1441 | 0.210 |
Why?
|
Animals | 45 | 2023 | 169335 | 0.210 |
Why?
|
Proto-Oncogene Proteins c-fos | 6 | 2011 | 581 | 0.210 |
Why?
|
Depression | 7 | 2023 | 8231 | 0.210 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 3 | 2016 | 693 | 0.210 |
Why?
|
Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 2 | 2015 | 19 | 0.200 |
Why?
|
Electroacupuncture | 3 | 2007 | 66 | 0.200 |
Why?
|
Hindlimb | 3 | 2017 | 516 | 0.200 |
Why?
|
Neurotoxins | 2 | 2017 | 240 | 0.200 |
Why?
|
Receptor, Muscarinic M2 | 3 | 2006 | 16 | 0.200 |
Why?
|
Inflammation | 10 | 2018 | 10868 | 0.190 |
Why?
|
Sciatica | 2 | 2013 | 97 | 0.190 |
Why?
|
Brain | 4 | 2024 | 27453 | 0.190 |
Why?
|
Double-Blind Method | 5 | 2024 | 12467 | 0.190 |
Why?
|
Anxiety Disorders | 2 | 2023 | 2749 | 0.190 |
Why?
|
Adult | 19 | 2023 | 223851 | 0.180 |
Why?
|
Middle Aged | 18 | 2024 | 223737 | 0.170 |
Why?
|
Dose-Response Relationship, Drug | 10 | 2018 | 10765 | 0.170 |
Why?
|
Touch | 4 | 2015 | 316 | 0.170 |
Why?
|
Female | 28 | 2024 | 397515 | 0.170 |
Why?
|
Protein Processing, Post-Translational | 1 | 2007 | 1966 | 0.170 |
Why?
|
Anxiety | 4 | 2023 | 4672 | 0.170 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2023 | 1048 | 0.160 |
Why?
|
Stroop Test | 1 | 2019 | 72 | 0.160 |
Why?
|
Drug Resistance | 3 | 2018 | 1599 | 0.160 |
Why?
|
gamma-Glutamyltransferase | 1 | 2019 | 144 | 0.160 |
Why?
|
Sodium Channels | 2 | 2011 | 341 | 0.160 |
Why?
|
Electrodes | 1 | 2021 | 617 | 0.160 |
Why?
|
Regression Analysis | 2 | 2019 | 6346 | 0.160 |
Why?
|
Humans | 36 | 2024 | 768970 | 0.160 |
Why?
|
Steroid 17-alpha-Hydroxylase | 1 | 2019 | 99 | 0.160 |
Why?
|
Imidazoles | 5 | 2017 | 1169 | 0.160 |
Why?
|
Receptors, Purinergic P2X | 2 | 2016 | 9 | 0.160 |
Why?
|
Pleurisy | 1 | 2018 | 54 | 0.150 |
Why?
|
Up-Regulation | 1 | 2007 | 4148 | 0.150 |
Why?
|
High-Intensity Focused Ultrasound Ablation | 1 | 2018 | 43 | 0.150 |
Why?
|
Cues | 1 | 2023 | 878 | 0.150 |
Why?
|
Sensory System Agents | 1 | 2017 | 24 | 0.150 |
Why?
|
Rotarod Performance Test | 2 | 2015 | 63 | 0.150 |
Why?
|
Buddhism | 1 | 2017 | 23 | 0.140 |
Why?
|
Nitric Oxide Donors | 1 | 2017 | 126 | 0.140 |
Why?
|
Christianity | 1 | 2017 | 53 | 0.140 |
Why?
|
Mice | 25 | 2023 | 82072 | 0.140 |
Why?
|
Ischemia | 3 | 2011 | 1900 | 0.140 |
Why?
|
Locus Coeruleus | 2 | 2012 | 243 | 0.140 |
Why?
|
Adrenal Medulla | 2 | 2007 | 56 | 0.140 |
Why?
|
Physical Stimulation | 4 | 2016 | 517 | 0.140 |
Why?
|
Alcohol-Related Disorders | 1 | 2019 | 243 | 0.140 |
Why?
|
Ethanol | 1 | 2023 | 1331 | 0.140 |
Why?
|
Drug Synergism | 3 | 2016 | 1762 | 0.140 |
Why?
|
Nitroglycerin | 1 | 2017 | 332 | 0.130 |
Why?
|
Personality Inventory | 1 | 2019 | 1018 | 0.130 |
Why?
|
Gap Junctions | 1 | 2018 | 230 | 0.130 |
Why?
|
Zymosan | 5 | 2008 | 134 | 0.130 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 2 | 2016 | 615 | 0.130 |
Why?
|
Yohimbine | 1 | 2015 | 62 | 0.130 |
Why?
|
Idazoxan | 3 | 2012 | 12 | 0.130 |
Why?
|
Phylogeny | 1 | 2023 | 2843 | 0.130 |
Why?
|
Skin | 2 | 2007 | 4506 | 0.130 |
Why?
|
Single-Blind Method | 1 | 2019 | 1586 | 0.130 |
Why?
|
Hyperprolactinemia | 1 | 2016 | 124 | 0.130 |
Why?
|
Connexin 43 | 1 | 2016 | 202 | 0.130 |
Why?
|
Mice, Inbred C57BL | 5 | 2017 | 22379 | 0.130 |
Why?
|
Religion | 1 | 2019 | 376 | 0.120 |
Why?
|
Cognition | 4 | 2023 | 7081 | 0.120 |
Why?
|
Enzyme Inhibitors | 5 | 2016 | 3726 | 0.120 |
Why?
|
Religion and Psychology | 1 | 2017 | 180 | 0.120 |
Why?
|
Impulsive Behavior | 1 | 2018 | 345 | 0.120 |
Why?
|
RGS Proteins | 1 | 2015 | 76 | 0.120 |
Why?
|
Wound Healing | 1 | 2006 | 2815 | 0.120 |
Why?
|
Cardiovascular Diseases | 1 | 2021 | 15661 | 0.120 |
Why?
|
Reaction Time | 2 | 2019 | 2101 | 0.120 |
Why?
|
Quality of Life | 4 | 2018 | 13510 | 0.120 |
Why?
|
Receptors, Purinergic P2Y1 | 1 | 2013 | 40 | 0.110 |
Why?
|
Cold Temperature | 1 | 2017 | 791 | 0.110 |
Why?
|
Arthritis, Experimental | 2 | 2008 | 293 | 0.110 |
Why?
|
Young Adult | 8 | 2020 | 60131 | 0.110 |
Why?
|
Dehydroepiandrosterone Sulfate | 2 | 2016 | 241 | 0.110 |
Why?
|
Dibenzothiazepines | 1 | 2013 | 102 | 0.100 |
Why?
|
N-Methylaspartate | 3 | 2019 | 231 | 0.100 |
Why?
|
Antineoplastic Agents | 1 | 2016 | 13698 | 0.100 |
Why?
|
Organ Specificity | 1 | 2017 | 1970 | 0.100 |
Why?
|
Epidermis | 1 | 2015 | 539 | 0.100 |
Why?
|
Bacteria | 1 | 2023 | 2216 | 0.100 |
Why?
|
Proteoglycans | 1 | 2016 | 809 | 0.100 |
Why?
|
Ambroxol | 1 | 2011 | 3 | 0.100 |
Why?
|
Schizophrenic Psychology | 1 | 2019 | 1651 | 0.100 |
Why?
|
Facial Expression | 1 | 2016 | 515 | 0.100 |
Why?
|
Physical Fitness | 1 | 2016 | 744 | 0.100 |
Why?
|
Receptors, Opioid, mu | 2 | 2015 | 170 | 0.100 |
Why?
|
Thiazolidinediones | 1 | 2015 | 461 | 0.100 |
Why?
|
Neuropsychological Tests | 3 | 2021 | 7148 | 0.100 |
Why?
|
Foot | 1 | 2015 | 577 | 0.100 |
Why?
|
Pyridines | 4 | 2017 | 2895 | 0.090 |
Why?
|
Stress, Physiological | 1 | 2019 | 1408 | 0.090 |
Why?
|
Control Groups | 1 | 2011 | 107 | 0.090 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2013 | 285 | 0.090 |
Why?
|
Random Allocation | 1 | 2015 | 2394 | 0.090 |
Why?
|
NG-Nitroarginine Methyl Ester | 1 | 2011 | 262 | 0.090 |
Why?
|
Ganglia, Sympathetic | 2 | 2007 | 65 | 0.090 |
Why?
|
Alzheimer Disease | 3 | 2019 | 8760 | 0.090 |
Why?
|
Sodium Channel Blockers | 1 | 2011 | 173 | 0.090 |
Why?
|
Anti-Inflammatory Agents | 3 | 2005 | 1811 | 0.090 |
Why?
|
Hypnotics and Sedatives | 1 | 2019 | 1191 | 0.090 |
Why?
|
Furans | 1 | 2011 | 202 | 0.090 |
Why?
|
Self Concept | 1 | 2016 | 1046 | 0.090 |
Why?
|
Implosive Therapy | 1 | 2012 | 127 | 0.090 |
Why?
|
Cross-Sectional Studies | 4 | 2019 | 26395 | 0.090 |
Why?
|
Chronic Disease | 2 | 2023 | 9384 | 0.080 |
Why?
|
Motor Activity | 3 | 2016 | 2713 | 0.080 |
Why?
|
Tyrosine 3-Monooxygenase | 2 | 2012 | 368 | 0.080 |
Why?
|
Quinolones | 1 | 2013 | 389 | 0.080 |
Why?
|
Blood Pressure | 2 | 2016 | 8544 | 0.080 |
Why?
|
Interleukin-1beta | 1 | 2015 | 1026 | 0.080 |
Why?
|
Antitussive Agents | 1 | 2008 | 19 | 0.080 |
Why?
|
Dopamine Antagonists | 1 | 2010 | 284 | 0.080 |
Why?
|
Computer Simulation | 2 | 2013 | 6291 | 0.080 |
Why?
|
Receptors, Purinergic P2 | 1 | 2010 | 152 | 0.080 |
Why?
|
Treatment Outcome | 6 | 2023 | 65480 | 0.080 |
Why?
|
Cyclopentanes | 1 | 2008 | 87 | 0.080 |
Why?
|
Spinal Cord Injuries | 1 | 2016 | 929 | 0.080 |
Why?
|
User-Computer Interface | 2 | 2012 | 1406 | 0.080 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2012 | 371 | 0.080 |
Why?
|
Functional Laterality | 1 | 2015 | 2267 | 0.080 |
Why?
|
Triterpenes | 1 | 2008 | 78 | 0.080 |
Why?
|
Adrenergic alpha-Antagonists | 1 | 2008 | 173 | 0.070 |
Why?
|
D-Amino-Acid Oxidase | 2 | 2019 | 26 | 0.070 |
Why?
|
Outpatients | 1 | 2016 | 1603 | 0.070 |
Why?
|
Self Report | 1 | 2019 | 3773 | 0.070 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2008 | 139 | 0.070 |
Why?
|
Mice, Knockout | 3 | 2017 | 14484 | 0.070 |
Why?
|
Sympathetic Fibers, Postganglionic | 1 | 2007 | 14 | 0.070 |
Why?
|
Analysis of Variance | 6 | 2013 | 6236 | 0.070 |
Why?
|
Suicidal Ideation | 1 | 2017 | 1462 | 0.070 |
Why?
|
Behavior, Animal | 1 | 2015 | 1862 | 0.070 |
Why?
|
Analgesics, Opioid | 2 | 2015 | 3838 | 0.070 |
Why?
|
Drug Therapy, Combination | 2 | 2015 | 6320 | 0.070 |
Why?
|
Amines | 1 | 2008 | 280 | 0.070 |
Why?
|
Ligation | 1 | 2007 | 446 | 0.070 |
Why?
|
Sympatholytics | 1 | 2006 | 82 | 0.070 |
Why?
|
Excitatory Amino Acid Agonists | 2 | 2017 | 142 | 0.070 |
Why?
|
Motivation | 1 | 2016 | 2025 | 0.070 |
Why?
|
Hexuronic Acids | 1 | 2006 | 145 | 0.070 |
Why?
|
Glucuronic Acid | 1 | 2006 | 150 | 0.070 |
Why?
|
Time Factors | 8 | 2016 | 40261 | 0.070 |
Why?
|
Microglia | 1 | 2015 | 1376 | 0.070 |
Why?
|
Patient Compliance | 1 | 2016 | 2701 | 0.060 |
Why?
|
Aniline Compounds | 1 | 2011 | 1095 | 0.060 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2015 | 3518 | 0.060 |
Why?
|
Silk | 1 | 2006 | 93 | 0.060 |
Why?
|
Neostigmine | 1 | 2005 | 68 | 0.060 |
Why?
|
Gene Expression Regulation | 5 | 2016 | 11932 | 0.060 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7861 | 0.060 |
Why?
|
Receptors, Opioid | 1 | 2006 | 145 | 0.060 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 2006 | 287 | 0.060 |
Why?
|
Sex Factors | 1 | 2019 | 10633 | 0.060 |
Why?
|
Adrenergic Antagonists | 1 | 2004 | 26 | 0.060 |
Why?
|
Aged | 9 | 2024 | 171786 | 0.060 |
Why?
|
Receptors, GABA-A | 1 | 2009 | 625 | 0.060 |
Why?
|
Aromatherapy | 1 | 2024 | 5 | 0.060 |
Why?
|
Oncogene Proteins v-fos | 3 | 2012 | 15 | 0.060 |
Why?
|
Age of Onset | 1 | 2011 | 3346 | 0.060 |
Why?
|
Leukocytes | 3 | 2008 | 2034 | 0.060 |
Why?
|
Pressure | 1 | 2007 | 1172 | 0.060 |
Why?
|
Adolescent | 4 | 2018 | 89244 | 0.060 |
Why?
|
Calcium Signaling | 1 | 2008 | 738 | 0.060 |
Why?
|
Cholinesterase Inhibitors | 1 | 2005 | 241 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3608 | 0.050 |
Why?
|
Norepinephrine | 1 | 2006 | 899 | 0.050 |
Why?
|
Odds Ratio | 1 | 2016 | 9684 | 0.050 |
Why?
|
Citrates | 2 | 2015 | 134 | 0.050 |
Why?
|
Mental Health | 1 | 2018 | 3275 | 0.050 |
Why?
|
Corticosterone | 1 | 2023 | 301 | 0.050 |
Why?
|
Inflammation Mediators | 2 | 2008 | 1890 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 2 | 2017 | 5707 | 0.050 |
Why?
|
Electric Stimulation | 1 | 2007 | 1742 | 0.050 |
Why?
|
Sympathectomy, Chemical | 3 | 2007 | 25 | 0.050 |
Why?
|
Dopamine | 1 | 2010 | 1596 | 0.050 |
Why?
|
Piperazines | 1 | 2013 | 2553 | 0.050 |
Why?
|
Membrane Glycoproteins | 1 | 2013 | 3713 | 0.050 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2008 | 1141 | 0.050 |
Why?
|
Epithelium | 1 | 2006 | 1607 | 0.050 |
Why?
|
Inpatients | 1 | 2013 | 2569 | 0.050 |
Why?
|
Risk Factors | 2 | 2021 | 74976 | 0.050 |
Why?
|
Comorbidity | 1 | 2016 | 10592 | 0.050 |
Why?
|
Drugs, Chinese Herbal | 1 | 2002 | 147 | 0.050 |
Why?
|
Perception | 1 | 2007 | 1209 | 0.050 |
Why?
|
Adrenergic Agonists | 1 | 2020 | 57 | 0.050 |
Why?
|
Catecholamines | 3 | 2007 | 389 | 0.050 |
Why?
|
Cytokines | 1 | 2016 | 7453 | 0.040 |
Why?
|
Phytotherapy | 1 | 2002 | 298 | 0.040 |
Why?
|
Adrenalectomy | 3 | 2007 | 348 | 0.040 |
Why?
|
Neurons | 4 | 2007 | 9519 | 0.040 |
Why?
|
3-Hydroxysteroid Dehydrogenases | 1 | 2019 | 34 | 0.040 |
Why?
|
Molsidomine | 1 | 2019 | 22 | 0.040 |
Why?
|
Ketoconazole | 1 | 2019 | 97 | 0.040 |
Why?
|
Sertraline | 1 | 2020 | 209 | 0.040 |
Why?
|
Antirheumatic Agents | 1 | 2008 | 1381 | 0.040 |
Why?
|
Dihydrotestosterone | 1 | 2019 | 195 | 0.040 |
Why?
|
Anticonvulsants | 1 | 2008 | 1924 | 0.040 |
Why?
|
Aging | 1 | 2017 | 8745 | 0.040 |
Why?
|
Drug Interactions | 3 | 2009 | 1418 | 0.040 |
Why?
|
Immunohistochemistry | 3 | 2006 | 11116 | 0.040 |
Why?
|
Cell Movement | 2 | 2008 | 5216 | 0.040 |
Why?
|
Follow-Up Studies | 3 | 2018 | 39394 | 0.040 |
Why?
|
Edema | 3 | 2007 | 766 | 0.040 |
Why?
|
Antiemetics | 1 | 2018 | 188 | 0.030 |
Why?
|
Prognosis | 1 | 2017 | 30046 | 0.030 |
Why?
|
Purinergic P2X Receptor Agonists | 1 | 2016 | 5 | 0.030 |
Why?
|
Pregnenolone | 1 | 2016 | 27 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2016 | 4862 | 0.030 |
Why?
|
Receptors, Interleukin-1 Type I | 1 | 2015 | 30 | 0.030 |
Why?
|
Choline O-Acetyltransferase | 2 | 2006 | 156 | 0.030 |
Why?
|
Menstruation Disturbances | 1 | 2016 | 143 | 0.030 |
Why?
|
Nausea | 1 | 2018 | 682 | 0.030 |
Why?
|
Dizziness | 1 | 2018 | 269 | 0.030 |
Why?
|
Nicotinic Antagonists | 2 | 2005 | 94 | 0.030 |
Why?
|
Sciatic Nerve | 1 | 2019 | 628 | 0.030 |
Why?
|
Muscarinic Antagonists | 2 | 2006 | 136 | 0.030 |
Why?
|
Vomiting | 1 | 2018 | 655 | 0.030 |
Why?
|
Prolactin | 1 | 2016 | 627 | 0.030 |
Why?
|
Membrane Proteins | 1 | 2011 | 7885 | 0.030 |
Why?
|
Purinergic P2Y Receptor Agonists | 1 | 2013 | 5 | 0.030 |
Why?
|
Down-Regulation | 2 | 2016 | 2942 | 0.030 |
Why?
|
Thrombosis | 1 | 2008 | 2956 | 0.030 |
Why?
|
Deoxyadenine Nucleotides | 1 | 2013 | 14 | 0.030 |
Why?
|
Mice, 129 Strain | 1 | 2015 | 369 | 0.030 |
Why?
|
Minocycline | 1 | 2015 | 170 | 0.030 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2015 | 299 | 0.030 |
Why?
|
Membrane Potentials | 1 | 2017 | 1090 | 0.030 |
Why?
|
MAP Kinase Kinase 4 | 1 | 2013 | 147 | 0.030 |
Why?
|
Flavonoids | 1 | 2017 | 447 | 0.030 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2016 | 365 | 0.030 |
Why?
|
Magnetic Resonance Imaging, Interventional | 1 | 2014 | 195 | 0.030 |
Why?
|
Adenosine Diphosphate | 1 | 2013 | 422 | 0.030 |
Why?
|
Microscopy, Immunoelectron | 1 | 2012 | 316 | 0.020 |
Why?
|
Cell Count | 2 | 2006 | 1833 | 0.020 |
Why?
|
Isoindoles | 1 | 2011 | 36 | 0.020 |
Why?
|
Stimulation, Chemical | 1 | 2011 | 305 | 0.020 |
Why?
|
Intraoperative Complications | 1 | 2018 | 1176 | 0.020 |
Why?
|
Blotting, Western | 1 | 2019 | 5033 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2019 | 2744 | 0.020 |
Why?
|
Ganglia, Spinal | 1 | 2013 | 530 | 0.020 |
Why?
|
Prefrontal Cortex | 1 | 2021 | 2237 | 0.020 |
Why?
|
Surgery, Computer-Assisted | 1 | 2018 | 1006 | 0.020 |
Why?
|
Headache | 1 | 2018 | 1264 | 0.020 |
Why?
|
Stereotaxic Techniques | 1 | 2013 | 559 | 0.020 |
Why?
|
Narcotic Antagonists | 1 | 2015 | 591 | 0.020 |
Why?
|
MAP Kinase Signaling System | 1 | 2017 | 1495 | 0.020 |
Why?
|
Adenosine Triphosphate | 1 | 2016 | 2003 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2018 | 6232 | 0.020 |
Why?
|
Child | 1 | 2018 | 80960 | 0.020 |
Why?
|
Muscimol | 1 | 2009 | 70 | 0.020 |
Why?
|
Bicuculline | 1 | 2009 | 96 | 0.020 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2011 | 564 | 0.020 |
Why?
|
GABA-A Receptor Antagonists | 1 | 2009 | 59 | 0.020 |
Why?
|
Oldenlandia | 1 | 2008 | 2 | 0.020 |
Why?
|
Memory | 1 | 2019 | 2209 | 0.020 |
Why?
|
GABA-A Receptor Agonists | 1 | 2009 | 86 | 0.020 |
Why?
|
GABA Agonists | 1 | 2009 | 106 | 0.020 |
Why?
|
Ferrous Compounds | 1 | 2008 | 41 | 0.020 |
Why?
|
Retrospective Studies | 1 | 2017 | 81903 | 0.020 |
Why?
|
Electrodes, Implanted | 1 | 2013 | 841 | 0.020 |
Why?
|
Dehydroepiandrosterone | 1 | 2009 | 259 | 0.020 |
Why?
|
Oxidants | 1 | 2008 | 168 | 0.020 |
Why?
|
Adrenergic Agents | 1 | 2007 | 72 | 0.020 |
Why?
|
Hormone Antagonists | 1 | 2007 | 108 | 0.020 |
Why?
|
Gliosis | 1 | 2008 | 246 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2008 | 687 | 0.020 |
Why?
|
Acetylcholinesterase | 1 | 2007 | 151 | 0.020 |
Why?
|
Mifepristone | 1 | 2007 | 151 | 0.020 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 2276 | 0.020 |
Why?
|
Thalamus | 1 | 2013 | 1049 | 0.020 |
Why?
|
Ultrasonography, Interventional | 1 | 2014 | 1524 | 0.020 |
Why?
|
Receptor, Serotonin, 5-HT1A | 1 | 2006 | 58 | 0.020 |
Why?
|
Muscarinic Agonists | 1 | 2006 | 91 | 0.020 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 1 | 2013 | 1988 | 0.020 |
Why?
|
Injections, Intraventricular | 1 | 2006 | 227 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2007 | 877 | 0.020 |
Why?
|
Hexamethonium | 1 | 2005 | 17 | 0.020 |
Why?
|
Autonomic Fibers, Preganglionic | 1 | 2005 | 8 | 0.020 |
Why?
|
Dinoprostone | 1 | 2008 | 597 | 0.020 |
Why?
|
Signal Transduction | 1 | 2008 | 23653 | 0.020 |
Why?
|
Oxidopamine | 1 | 2005 | 170 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2013 | 2149 | 0.020 |
Why?
|
Pirenzepine | 1 | 2005 | 116 | 0.020 |
Why?
|
Atropine | 1 | 2005 | 244 | 0.020 |
Why?
|
Air | 1 | 2005 | 187 | 0.020 |
Why?
|
Exudates and Transudates | 1 | 2005 | 175 | 0.020 |
Why?
|
Receptors, Steroid | 1 | 2005 | 156 | 0.010 |
Why?
|
Presynaptic Terminals | 1 | 2007 | 302 | 0.010 |
Why?
|
Peroxidase | 1 | 2007 | 610 | 0.010 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2008 | 627 | 0.010 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2007 | 660 | 0.010 |
Why?
|
Femoral Artery | 1 | 2008 | 829 | 0.010 |
Why?
|
Neurosurgical Procedures | 1 | 2014 | 2110 | 0.010 |
Why?
|
Neural Pathways | 1 | 2013 | 3120 | 0.010 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2007 | 1243 | 0.010 |
Why?
|
Heparin | 1 | 2008 | 1636 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2013 | 8559 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2016 | 59739 | 0.010 |
Why?
|
Lung | 1 | 2018 | 10099 | 0.010 |
Why?
|
Animals, Newborn | 1 | 2005 | 2683 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2016 | 15951 | 0.010 |
Why?
|
Acute Disease | 1 | 2008 | 7245 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2015 | 22296 | 0.010 |
Why?
|
Piperidines | 1 | 2005 | 1667 | 0.010 |
Why?
|
Mental Disorders | 1 | 2016 | 6876 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 2005 | 1892 | 0.010 |
Why?
|
Pyrimidines | 1 | 2006 | 3048 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2002 | 3232 | 0.010 |
Why?
|
Prospective Studies | 1 | 2016 | 54962 | 0.010 |
Why?
|
Radiography | 1 | 2002 | 6991 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2018 | 36854 | 0.010 |
Why?
|